ALLYX THERAPEUTICS INC

Allyx Therapeutics is a clinical-stage biotechnology company developing disease-modifying therapies for Alzheimer's and Parkinson's disease by targeting the underlying cause of synapse dysfunction and loss. Its lead candidate ALX-001 is an orally bioavailable small molecule that has demonstrated reversal of learning and memory deficits in preclinical models and has completed Phase 1 studies showing safety, tolerability, and full brain receptor occupancy. The company is advancing ALX-001 into Phase 2 proof-of-concept studies for both Alzheimer's and Parkinson's disease, supported by NIH SBIR grants and Alzheimer's Association funding.